Market Insight | Zai Lab Soars Over 11% on Positive DLL3 ADC Clinical Data for Extensive-Stage Small Cell Lung Cancer Phase 1a Trial

Zai Lab opened more than 11%, as of the time of publication, it rose by 11.88% to HKD 24.95, with a turnover of HKD 4.2939 million. On the news front, on October 24th, Zai Lab announced the latest data from the global Phase 1a clinical trial of ZL-1310 in an oral presentation at the EORTC-NCI-AACR (ENA) conference. ZL-1310 is a potential best-in-class new generation antibody-drug conjugate (ADC) targeting Delta-like ligand 3 (DLL3). In patients with extensive-stage small cell lung cancer (SCLC) in relapse, ZL-1310 achieved an objective response rate (ORR) of 74% at all tested dose levels. ZL-1310 demonstrated good tolerability at all dose levels, with most treatment-emergent adverse events (TEAE) being Grade 1 or Grade 2